The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.

China-based oncology therapy developer Antengene floated on Friday in an initial public offering sized at about HK$2.79bn ($360m) that achieved exits for corporates WuXi AppTec, Celgene, Taikang and Tigermed, DealStreetAsia reported.

The company issued just over 154 million shares on the main board of the Hong Kong Stock Exchange priced at the top of the IPO’s HK$15.80-HK$18.08 range. Its shared opened at HK$19.60 on their first day of trading, giving the company a market cap of about $1.69bn.

A total…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn